Physician profile
Yaser Elnahar
NPI 1831409531
$5,845.60
in general payments reported to CMS, 2019-2025
38 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $179 · 2021: $439 · 2022: $878 · 2023: $1,438 · 2024: $1,357 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,501.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $977.04 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $694.56 | 2022-2025 | Sapien 3 Ultra Resilia, Konect Resilia |
| Amgen INC. | $590.49 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $396.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $393.25 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $379.02 | 2019-2024 | Watchman, Varithena Administration Pack |
| Altathera Pharmaceuticals LLC | $304.95 | 2023 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $283.66 | 2021-2025 | |
| Abbott Laboratories | $257.86 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Abiomed | $137.56 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $122.37 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $121.89 | 2022-2025 | Onpattro |
| Medtronic Vascular, INC. | $118.94 | 2019 | |
| Merck Sharp & Dohme LLC | $113.20 | 2022-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $71.55 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $60.31 | 2019-2024 | Injectafer |
| Philips North America LLC | $58.50 | 2022-2023 | |
| Inspire Medical Systems, INC. | $56.36 | 2023-2024 | Inspire |
| Novo Nordisk INC | $51.30 | 2024 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $50.23 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $47.37 | 2020-2025 | Nexletol |
| Kiniksa Pharmaceuticals, Ltd. | $44.66 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.09 | 2020-2025 | Lifevest |
| Amarin Pharma, INC. | $43.93 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $43.07 | 2024 | Optimizer |
| Baxter Healthcare | $41.93 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $41.27 | 2019 | |
| Tactile Systems Technology INC | $40.42 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.35 | 2021-2023 | Jardiance |
| Bridgebio Pharma, INC. | $32.33 | 2025 | Attruby |
| Heartflow, INC. | $31.25 | 2024 | |
| United Therapeutics Corporation | $29.54 | 2022-2024 | Tyvaso |
| Cleerly, INC. | $29.04 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Kowa Pharmaceuticals America, INC. | $26.28 | 2021-2022 | |
| Biocompatibles, INC. | $20.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.59 | 2025 | |
| Cvrx, INC. | $17.19 | 2024 | Barostim Neo System |
| Medtronic, INC. | $15.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaser Elnahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.